Keros Therapeutics (KROS) EBIT Margin (2019 - 2025)
Keros Therapeutics filings provide 6 years of EBIT Margin readings, the most recent being 5072.79% for Q4 2025.
- On a quarterly basis, EBIT Margin fell 1555586.0% to 5072.79% in Q4 2025 year-over-year; TTM through Dec 2025 was 27.66%, a 17566650.0% decrease, with the full-year FY2025 number at 27.69%, changed N/A from a year prior.
- EBIT Margin hit 5072.79% in Q4 2025 for Keros Therapeutics, down from 107.87% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 10483.07% in Q4 2024 to a low of 541000.0% in Q3 2023.
- Median EBIT Margin over the past 5 years was 219.16% (2025), compared with a mean of 54468.25%.
- Biggest five-year swings in EBIT Margin: soared 52588222bps in 2024 and later tumbled -1555586bps in 2025.
- Keros Therapeutics' EBIT Margin stood at 27.18% in 2021, then plummeted by -393bps to 134.03% in 2022, then crashed by -24137bps to 32486.01% in 2023, then soared by 132bps to 10483.07% in 2024, then crashed by -148bps to 5072.79% in 2025.
- The last three reported values for EBIT Margin were 5072.79% (Q4 2025), 107.87% (Q3 2025), and 219.16% (Q2 2025) per Business Quant data.